The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 678 participants.

Also called NCT01081834

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 678 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01081834
Other papers using this trial's data
  • Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study Current medical research and opinion, 2014-02 DOI, PubMed 24073995

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Colombia, Estonia, Guatemala, Iceland, India, Lithuania, Malaysia, Mexico, Philippines, Poland, Puerto Rico, Romania, South Africa, South Korea, Spain, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01081834. Randomized; triple masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2011-08 (actual). Results posted on 2013-06-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Canagliflozin
Intervention (Drug)
Placebo
Intervention (Drug)
Sitagliptin
Lead sponsor
Janssen Research & Development, LLC (class: industry)

Record details

Record id
cardio:ct-nct01081834
Content hash
23c5a83a07b53202cec13f69c78e4e7407877839aef61196c302c4f2bd8f138c